AstraZeneca is expanding its planned investment in a new manufacturing facility in Virginia to $4,5 billion, an increase of $500 million. The facility in Albemarle County will manufacture weight management, metabolism and cancer drugs, including oral GLP-1s and antibody drug conjugates (ADCs). The investment will create approximately 3,600 direct and indirect jobs and is part of the company’s $50 billion investment in the U.S. The facility is expected to be operational within four to five years.
|
Published October 10, 2025
AstraZeneca invests $4,5 billion in Virginia
Text:
News Desk [email protected]
Notes
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
Egetis reports positive results from the ReTRIACt study
Mikael Dolsten withdraws his nomination to Novo's board
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account